With multiple delivery methods in development, Starton can expand the number of medicines it is able to deliver continuously, based on patients’ individualized needs and provide multiple avenues for success. 

Product Active Indication Preclinical Phase 1 Phase 1b Phase 2 Phase 3
STAR-LLD-SCsubcutaneous infusion
Lenalidomide (Revlimid®)
Multiple myeloma (MM)
STAR-LLD-SCsubcutaneous infusion
Lenalidomide (Revlimid®)
Chronic lymphocytic leukemia (CLL)
STAR-LLD-TDStransdermal patch
Lenalidomide (Revlimid®)
Multiple myeloma (MM)
STAR-LLD-TDStransdermal patch
Lenalidomide (Revlimid®)
Chronic lymphocytic leukemia (CLL)
STAR-LLD- OBDSOn body delivery system
Lenalidomide (Revlimid®)
Multiple myeloma (MM)
STAR-LLD- OBDSOn body delivery system
Lenalidomide (Revlimid®)
Chronic lymphocytic leukemia (CLL)

* other active ingredients are being researched at our facility that have not yet been disclosed

Subcutaneous delivery has broader applicability with multiple ambulatory pumps registered and available in the market and a growing number of on-body injectors. For this reason, Starton began the development of STAR-LLD using an ambulatory pump. This allowed us to get into the clinic sooner. 

Transdermal drug delivery patch is a method of delivering drugs systemically by applying a drug formulation onto intact and healthy skin. 

An On Body Delivery System is a wearable pump/patch combination for continuous subcutaneous delivery.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.